GlassScriptPhysician profile
Christopher M Spearman
NPI 1609263532
$67,899.93
in general payments reported to CMS, 2019-2025
30 companies · $36K in 2025
The $36K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $619 · 2021: $1,360 · 2022: $2,655 · 2023: $6,558 · 2024: $21K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $9,007 · Consulting Fee: $8,714 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,700 · Travel and Lodging: $5,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,043.89 |
| Food and Beverage | $9,006.73 |
| Consulting Fee | $8,713.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,700.00 |
| Travel and Lodging | $5,501.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $37,762.95 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $11,074.54 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Ic-8 Apthera Iol |
| Glaukos Corporation | $8,282.67 | 2019-2025 | Idosetr, Idose Tr, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $4,120.94 | 2019-2025 | Clareon, Hydrus Microstent, Centurion |
| Tarsus Pharmaceuticals, INC. | $2,002.63 | 2024-2025 | Xdemvy |
| Allergan, INC. | $1,039.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $467.90 | 2020-2023 | |
| Alcon Research LLC | $428.81 | 2023 | |
| Abbvie INC. | $401.79 | 2022-2025 | Lumigan, Durysta, Alphagan P |
| Ivantis, INC | $354.17 | 2021 | |
| Biotissue Holdings INC. | $300.56 | 2021-2025 | |
| New World Medical,INC. | $298.65 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Horizon Therapeutics Plc | $298.06 | 2022-2023 | Tepezza |
| Ocular Therapeutix, INC. | $270.45 | 2022-2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $156.53 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $112.50 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $107.32 | 2021 | |
| Thea Pharma INC. | $63.44 | 2024-2025 | Iyuzeh |
| Amgen INC. | $63.15 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.72 | 2021 | |
| Oyster Point Pharma, INC. | $45.93 | 2023-2025 | Tyrvaya, Ryzumvi |
| Genentech USA, INC. | $45.80 | 2023-2024 | Vabysmo |
| Rxsight INC | $28.53 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Eyevance Pharmaceuticals LLC | $24.95 | 2022 | |
| Dompe US, INC. | $22.39 | 2025 | Oxervate |
| Harrow Eye, LLC | $17.48 | 2024 | Vevye |
| Akorn, INC. | $16.96 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.59 | 2021 | |
| Apellis Pharmaceuticals, INC. | $12.13 | 2022 | |
| Omeros Corporation | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Spearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.